Clinical trial NCT04473573: Spartan Cube CYP2C19 Inter Laboratory Reproducibilty Study
Official title: Spartan Cube CYP2C19 Inter Laboratory Reproducibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Genotyping Techniques
Keywords: Reproducibility of Results
CYP2C19
Lead sponsor: Spartan Bioscience Inc.
Sponsor class: INDUSTRY
Collaborators: name: Children's Hospital of Eastern Ontario
name: The Ottawa Hospital
name: The University of Ottawa Heart Institute
First posted: 2020-07-16
Enrollment: 8
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: All subjects receive the same number and type of test for the duration of the study.
Primary purpose: SCREENING

Brief summary: The study verifies that the Spartan Cube CYP2C19 System generates reproducible results under multi-variant conditions including test site (three different test sites), operators (two operators per site), testing days (five non-consecutive days per site), and test kit lot (three different lots).

Detailed description: The reproducibility study (VNV-00227) is aimed at assessing the performance of the Spartan Cube CYP2C19 product under multi-variant conditions that include test site, operators, testing days, and reagent lots. The sections below address how these variables were tested.

This study will be performed by a total of six operators at three test sites. At each site, two operators will conduct buccal sample collection and analysis. Operators include individuals who are technologists, technicians, and/or nurses. The buccal samples will be loaded in the Cube within one hour after buccal swab collection. Furthermore, results will be generated using multiple platforms (Spartan Cube, computer, and printer) and the same platforms will be used at each site. At each site, a total of 64 (8 subjects/operator x 2 operators x 2 sessions x 2 sub-sessions (replicates)) tests will be run on five non-consecutive days. Each day includes 2 sessions and 2 sub-sessions (total 4 collection times) in which samples will be collected. Test subject to platform pairing is not required, results will be generated on one of the platforms per session. This means that each site will generate a total of 320(64 obs./day x 5 days) results over the entire duration of the study.

To determine lot-to-lot reproducibility of test kits, three different lots will be evaluated. For this, two lots will be tested at each site. Each operator will use two lots per session on each testing day. Each replicate only includes a single lot of test kits.

All results generated by the Spartan Cube CYP2C19 System will be compared with the bi-directional sequencing results.

Eligibility criteria: Inclusion Criteria:

* available for travel to three different sites, on 5 non-consecutive days.

Exclusion Criteria:

* none

Primary outcomes:
measure: % Agreement of test results generated on the Spartan Cube CYP2C19 System and bidirectional sequencing
timeFrame: Through study completion; anticipated to be less than 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: Children's Hospital of Eastern Ontario
state: Ontario
city: Ottawa
country: Canada
facility: Ottawa Hospital Research Institute
state: Ontario
city: Ottawa
country: Canada
facility: The Univeristy of Ottawa Heart Institute
state: Ontario
Study officials:
affiliation: Spartan Bioscience
name: Shaimaa Ahmed, PhD
role: PRINCIPAL_INVESTIGATOR
References: